NEW YORK (GenomeWeb News) – LabCorp has obtained an exclusive license granting it access to MGMT methylation-related IP technology developed by the molecular diagnostics company OncoMethylome Sciences, the companies announced today.

The move will allow LabCorp to do commercial MGMT methylation laboratory testing in the US and Canada, with limited exceptions. OncoMethylome also named LabCorp’s Esoterix Clinical Trials Services Division as one of its preferred subcontractors for clinical trial MGMT methylation testing services.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.